NCT06303193View on ClinicalTrials.gov

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

January 1, 2030

Study Completion Date

January 1, 2035

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

pacritinib

Pacritinib will be administered orally on a continuous basis for 28 day cycles without a rest period between cycles. Dose assigned by dose level/phase.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT06303193 - Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | Biotech Hunter | Biotech Hunter